BIOMAT Database Logo BIOMAT Database Logo

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. 1998

M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Ohio 44106, USA. MXL6@po.cwru.edu

Human immunodeficiency virus (HIV)-1 infection is associated with progressive cell-mediated immune deficiency and abnormal immune activation. Although highly active antiretroviral therapy regimens can increase circulating CD4 T lymphocyte counts and decrease the risk of opportunistic complications, the effects of these treatments on immune reconstitution are not well understood. In 44 persons with moderately advanced HIV-1 infection, after 12 weeks of treatment with zidovudine, lamivudine, and ritonavir, plasma HIV-1 RNA fell a median of 2.3 logs (P < .0001). Circulating numbers of naive and memory CD4 T lymphocytes (P < .001), naive CD8 T lymphocytes (P < .004), and B lymphocytes (P < .001) increased. Improved lymphocyte proliferation to certain antigens and a tendency to improvement in delayed-type hypersensitivity also were seen. Dysregulated immune activation was partially corrected by this regimen; however, the perturbed expression of T cell receptor V regions in the CD4 and CD8 T lymphocyte populations was not significantly affected. Ongoing studies will ascertain if longer durations of virus suppression will permit more complete immune restoration.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D001402 B-Lymphocytes Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation. B-Cells, Lymphocyte,B-Lymphocyte,Bursa-Dependent Lymphocytes,B Cells, Lymphocyte,B Lymphocyte,B Lymphocytes,B-Cell, Lymphocyte,Bursa Dependent Lymphocytes,Bursa-Dependent Lymphocyte,Lymphocyte B-Cell,Lymphocyte B-Cells,Lymphocyte, Bursa-Dependent,Lymphocytes, Bursa-Dependent

Related Publications

M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
July 2000, AIDS (London, England),
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
July 1996, JAMA,
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353.
January 2008, HIV clinical trials,
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Can immune markers predict subsequent discordance between immunologic and virologic responses to antiretroviral therapy? Adult AIDS Clinical Trials Group.
August 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.
February 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Open-label phase I study of combination therapy with zidovudine and interferon-beta in patients with AIDS-related Kaposi's sarcoma: AIDS Clinical Trials Group Protocol 057.
March 1998, Cytokines, cellular & molecular therapy,
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group.
March 1995, Annals of internal medicine,
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
June 1999, Clinical pharmacology and therapeutics,
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
December 2001, Annals of internal medicine,
M M Lederman, and E Connick, and A Landay, and D R Kuritzkes, and J Spritzler, and M St Clair, and B L Kotzin, and L Fox, and M H Chiozzi, and J M Leonard, and F Rousseau, and M Wade, and J D Roe, and A Martinez, and H Kessler
Combination antiretroviral treatment for women previously treated only in pregnancy: week 24 results of AIDS clinical trials group protocol a5227.
April 2014, Journal of acquired immune deficiency syndromes (1999),
Copied contents to your clipboard!